VENA vs. CCLD, BMR, LGCL, RTC, WAVS, DUOT, MNDO, AOGO, JG, and AGMH
Should you be buying Venus Acquisition stock or one of its competitors? The main competitors of Venus Acquisition include CareCloud (CCLD), Beamr Imaging (BMR), Lucas GC (LGCL), Baijiayun Group (RTC), Western Acquisition Ventures (WAVS), Duos Technologies Group (DUOT), MIND C.T.I. (MNDO), Arogo Capital Acquisition (AOGO), Aurora Mobile (JG), and AGM Group (AGMH). These companies are all part of the "computer software" industry.
Venus Acquisition vs.
CareCloud (NASDAQ:CCLD) and Venus Acquisition (NASDAQ:VENA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk.
10.2% of CareCloud shares are held by institutional investors. Comparatively, 67.0% of Venus Acquisition shares are held by institutional investors. 38.4% of CareCloud shares are held by insiders. Comparatively, 22.7% of Venus Acquisition shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Venus Acquisition has a net margin of 0.00% compared to CareCloud's net margin of -35.25%. Venus Acquisition's return on equity of -2.37% beat CareCloud's return on equity.
In the previous week, CareCloud had 1 more articles in the media than Venus Acquisition. MarketBeat recorded 1 mentions for CareCloud and 0 mentions for Venus Acquisition. CareCloud's average media sentiment score of 0.00 equaled Venus Acquisition'saverage media sentiment score.
Venus Acquisition has lower revenue, but higher earnings than CareCloud.
CareCloud has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Venus Acquisition has a beta of -0.05, indicating that its share price is 105% less volatile than the S&P 500.
CareCloud received 8 more outperform votes than Venus Acquisition when rated by MarketBeat users.
CareCloud currently has a consensus target price of $3.67, indicating a potential upside of 18.66%. Given CareCloud's stronger consensus rating and higher possible upside, equities analysts plainly believe CareCloud is more favorable than Venus Acquisition.
Summary
CareCloud beats Venus Acquisition on 8 of the 13 factors compared between the two stocks.
Get Venus Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for VENA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Venus Acquisition Competitors List
Related Companies and Tools
This page (NASDAQ:VENA) was last updated on 1/22/2025 by MarketBeat.com Staff
Free VENA Stock Alerts